Skip to content
FDMT·Nasdaq·US

4D Molecular Therapeutics

4D Molecular Therapeutics is a late-stage biotechnology company developing durable, disease-targeted genetic medicines using customized and evolved adeno-associated virus (AAV) vectors invented through its proprietary Therapeutic Vector Evolution platform. It focuses on clinical-stage product candidates for retina and lung diseases, including lead candidate 4D-150 for wet AMD and DME, 4D-175 for geographic atrophy, and 4D-710 and 4D-725 for cystic fibrosis and alpha-1 antitrypsin deficiency lung disease.

Source: SEC 10-K Mar 18, 2026

Thematic Position

FDMT

Relationship Groups

Competitors18

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

10 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

patent regulationlitigation forum
EU Unified Patent Court creates new forum for competitors to revoke patents
SEC 10-QAug 13, 2026

The full regulatory passage is part of the Pro plan.

14 more · Regulatory and geopolitical insights are part of the Pro plan.